Loading
A phase 1/2 trial of Fulvestrant, Letrozole in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07288359 by Novartis Pharmaceuticals, with 205 participants planned, started 2025-12-29 and due to reach its primary completion in 2031-05-09. Interventions recorded: GVV858, Fulvestrant, Letrozole. Conditions listed: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.
Shares Letrozole (and other aromatase inhibitors), Fulvestrant.
Shares Fulvestrant, Novartis.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Shares Novartis, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/